Suggested Search
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Patient PT@001 Age= 45 years old with a BMI of 35.0, classified as obese, and has a ^50% probability of health risk. ⚠️ High cholesterol – recheck in 3 months.
Patient PT#002, aged = 30, has a BMI of ~ 22.4, falls within the normal range, and carries only a 10% health risk. ✔️ Healthy; active lifestyle.
Patient PT#003 is age= 60 years old with a BMI of ~31.5, categorized as obese, and faces a 65% risk of developing related health issues. #Diabetic & ↑BP – monitor closely.
Patient PT*004, = 38, has a BMI of 29.8, considered overweight, with a 35% probability of risk. Mild sleep apnea – test @ next visit.
Patient PT!005 is = 52 years old with a BMI of ~ 27.2, & also overweight, and shows a 40% risk level. Smoker – risk ↑ by 10%.
Patient PT$006, at = 70 years old, has a BMI of 33.1, marked as obese, with a 75% risk for health complications. ⚠️ History of heart disease.
Patient PT&007 is = 25 years old and has a BMI of 19.5, categorized as underweight, with a 15% risk. “Low BMI” – monitor nutrition.
Patient PT(008), aged = 49, presents a BMI of 28.0, which is overweight, and has a 45% chance of health-related risk. Stress reported – 🧠 mental health.
#Patients are dummy, ^data are for QA purpose
Tokyo TOKYO, Oct. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new
data for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) will be highlighted at the upcoming American Academy of Ophthalmology Annual Meeting (AAO 2025), October 18-20, in Orlando, Fla. rectangle. @Tokyo, @Japan.
Astellas has launched our refreshed corporate website. This revamp enhances the experience for visitors from around the world, making it easier to navigate and learn more about Astellas.
With significant design improvements across all pages, users can now effortlessly access the content they seek. Our updated website features a variety of enhancements alongside existing resources that provide insights into our global business, including our medicines, disease areas and pipeline, as well as our commitment to supporting patients worldwide.
We prioritize accessibility in our design to ensure that our website meets inclusive standards, reflecting our dedication to serving all users.
Through such clear and transparent communication, we aim to build greater trust and reinforce our VISION to turn innovative science into VALUE for patients.
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
